Magnolia Medical Technologies makes a product that aims to reduce the rate of false positive diagnoses of sepsis.
Seattle-based Magnolia Medical Technologies has raised $13.8 million to continue developing a product that aims to provide accurate blood tests.
Magnolia makes the SteriPath blood-collection system, which is meant to decrease the number of false positives for sepsis, a complication of a bloodstream infection that is often treated with antibiotics and can be life-threatening.
Such false positives can mean that patients are given procedures and treatments they don’t need, exposing them to more risk, Magnolia said in a news release announcing the funding. More than 1 million people in the U.S. are misdiagnosed with sepsis each year, the company said.
Menlo Park, Calif.-based HealthQuest Capital led the funding round and announced managing partner Garheng Kong would join Magnolia’s board.
Most Read Business Stories
- Early 787 test plane is dismantled for reuse, recycling, or scrap
- The unspoken factor in Amazon’s search for a new home: Jeff Bezos’ support for gay rights
- Apple’s New iPad is the best tablet for almost everybody | Tech review
- Why are Seattle-area home prices so high? | Mike Rosenberg
- Seattle will be too expensive for you when you retire, longtimer is told | Money Makeover
SteriPath is commercially available, and the company will use the investment to expand the product into hospitals.